BioMarin (BMRN) Licenses Factor VIII for Hemophilia A from UCL

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has licensed a Factor VIII gene therapy program for hemophilia A from University College London (UCL) and St. Jude Children's Research Hospital. The company expects to select a development candidate this year, initiate and complete IND-enabling toxicology studies next year and initiate proof of concept human studies by the end of 2014. The license and commitment to support the research program was made possible by UCL Business, UCL's wholly-owned technology transfer company, working with Professor Amit Nathwani of the UCL Cancer Institute.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $59 at H.C. Wainwright
• Lazard Global Total Return fund declares $0.1534 monthly distribution
• Nuvectis Pharma (NVCT) files $200M mixed shelf